设为首页收藏本站

中国病毒学论坛|我们一直在坚持!

 找回密码
 立即注册

QQ登录

只需一步,快速开始

搜索
热搜: 活动 交友 discuz

cell report:MDA-5抗病毒免疫调节新机制

查看数: 1654 | 评论数: 1 | 收藏 0
关灯 | 提示:支持键盘翻页<-左 右->
    组图打开中,请稍候......
发布时间: 2015-4-16 12:59

正文摘要:

天然免疫应答对于抵抗病毒的感染十分重要。RIG-I与MDA-5是最常见的细胞内部识别病毒RNA的信号分子,它们的识别与激活能够传递胞内的抗病毒免疫反应。MDA-5能够识别较长的双链RNA分子,而RIG-I识别的序列长度较短。对 ...

回复

ipsvirus 发表于 2015-4-16 13:00:24
本帖最后由 ipsvirus 于 2015-4-16 13:03 编辑

RIOK3-Mediated Phosphorylation of MDA5 Interferes with Its Assembly and Attenuates the Innate Immune Response

Ken Takashima, Hiroyuki Oshiumi, Hiromi Takaki, Misako Matsumoto, and Tsukasa Seya


Highlights
•RIOK3 attenuates MDA5-mediated innate immune response
•RIOK3 mediates phosphorylation of MDA5 Ser-828
•Phosphorylation of MDA5 Ser-828 disrupts its assembly and signaling
Summary
MDA5 is a cytoplasmic viral double-stranded RNA (dsRNA) sensor and triggers type I interferon (IFN) production. MDA5 assembles along viral dsRNA, leading to the formation of an MDA5 filament required for activating the MAVS adaptor. A recent study has revealed that PP1α and PP1γ phosphatases are responsible for dephosphorylating MDA5 and are essential for its activation. Here, we identified RIO kinase 3 (RIOK3) as a protein kinase that phosphorylates the MDA5 C-terminal region. RIOK3 knockout strongly enhanced type I IFN and IFN-inducible gene expression following measles virus infection. Conversely, the ectopic expression of RIOK3 or a phosphomimetic MDA5-S828D mutation attenuated MDA5-mediated signaling. Moreover, RIOK3-mediated MDA5 phosphorylation impaired MDA5 multimer formation, indicating that MDA5 C-terminal phosphorylation interferes with MDA5 filament formation and suppresses its signaling. Our data revealed a regulatory mechanism underlying the activation of the cytoplasmic viral RNA sensor MDA5 in both uninfected and virus-infected cells.

http://www.cell.com/cell-reports/abstract/S2211-1247(15)00296-X

QQ|论坛App下载|Archiver|小黑屋|中国病毒学论坛    

GMT+8, 2024-11-24 03:45 , Processed in 0.075783 second(s), 32 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表